JP2014005265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014005265A5 JP2014005265A5 JP2012195912A JP2012195912A JP2014005265A5 JP 2014005265 A5 JP2014005265 A5 JP 2014005265A5 JP 2012195912 A JP2012195912 A JP 2012195912A JP 2012195912 A JP2012195912 A JP 2012195912A JP 2014005265 A5 JP2014005265 A5 JP 2014005265A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- deuterium
- hydrogen
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052805 deuterium Inorganic materials 0.000 claims 27
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 5
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004429 atoms Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000155 isotopic Effects 0.000 claims 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 2
- 229960001433 Erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008943 Chronic leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 206010046885 Vaginal cancer Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000001342 fallopian tube cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000005746 pituitary adenoma Diseases 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663221P | 2012-06-22 | 2012-06-22 | |
| US61/663,221 | 2012-06-22 | ||
| US201261680885P | 2012-08-08 | 2012-08-08 | |
| US61/680,885 | 2012-08-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014005265A JP2014005265A (ja) | 2014-01-16 |
| JP2014005265A5 true JP2014005265A5 (sr) | 2015-10-01 |
Family
ID=49892488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012195912A Pending JP2014005265A (ja) | 2012-06-22 | 2012-09-06 | ピラゾール置換アミノ−ヘテロアリール化合物の誘導体 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2014005265A (sr) |
| CN (1) | CN103509008A (sr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103304552B (zh) * | 2012-03-09 | 2016-12-28 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
| CN104650049B (zh) * | 2013-08-28 | 2018-06-08 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
| CN108350006B (zh) * | 2015-11-27 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途 |
| CN110407856B (zh) | 2016-03-03 | 2021-04-13 | 深圳市塔吉瑞生物医药有限公司 | 一种大环化合物及包含该化合物的组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA87153C2 (ru) * | 2004-08-26 | 2009-06-25 | Пфайзер Инк. | Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы |
| ATE488237T1 (de) * | 2005-12-05 | 2010-12-15 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| CN101967140A (zh) * | 2010-09-14 | 2011-02-09 | 郑州泰基鸿诺药物科技有限公司 | 氘代克里唑蒂尼及其衍生物、制备方法和应用 |
-
2012
- 2012-09-05 CN CN201210326710.4A patent/CN103509008A/zh active Pending
- 2012-09-06 JP JP2012195912A patent/JP2014005265A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014102935A (ru) | Кризотиниб для применения в лечении рака | |
| HRP20201334T1 (hr) | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| JP2018510850A5 (sr) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| RU2018104269A (ru) | Полиморфная форма диарильного макроцикла | |
| RU2017139515A (ru) | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там | |
| JP2007153894A5 (sr) | ||
| RU2008122471A (ru) | Способ лечения аномального роста клеток | |
| JP2020514409A5 (sr) | ||
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2011515397A5 (sr) | ||
| TR201800962T4 (en) | CDC7 KINAZI INHIBITORS AND THEIR USAGE | |
| JP2020105190A5 (sr) | ||
| RU2010121647A (ru) | Полиморфы ингибитора c-met/hgfr | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| JPWO2019150305A5 (sr) | ||
| JP2015232006A5 (sr) | ||
| JP2008521928A5 (sr) | ||
| RU2014124005A (ru) | Комбинация инотузумаба озогамицина и торизела для лечения рака | |
| JP2014514317A5 (sr) | ||
| JP2014005265A5 (sr) | ||
| EA201201154A1 (ru) | Ингибиторы фосфатидилинозит-3-киназы и способы их применения | |
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2007530526A5 (sr) |